NL-OMON40764已完成4 期
A Post-market Study Evaluating the Prodigy Neuromodulation System for the Management of Failed Back Surgery Syndrome or Chronic Intractable Pain of the Trunk and/or limbs - Prodigy-I study
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •o Patient with chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome or intractable low back and/or leg pain
- •o Patient is considered by the investigator as a candidate for implantation of a SCS system
- •o Patient is >= 18 years of age
- •o Patient must be willing and able to comply with study requirements
- •o Patient must indicate his/her understanding of the study and willingness to participate by signing an appropriate Informed Consent Form
排除标准
- •o Patient is immune-compromised
- •o Patient has history of cancer requiring active treatment in the last 6 months
- •o Patient has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the last 6 months
- •o Patients with a SCS system or implantable infusion pump implanted previously
- •o Patient has a life expectancy of less than one year
- •o Patient is pregnant or is planning to become pregnant during the duration of the investigation
- •o Patient is unable to comply with the follow up schedule
- •o Patient needing legally authorized representative
- •o Patient unable to read and write
- •o Patient is currently participating in another clinical investigation with an active treatment arm
研究者
相似试验
进行中(未招募)
2 期
COVID-19 vaccines in pregnancyCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN15279830St George's, University of London319
招募中
3 期
A clinical study to determine the efficacy and safety of 101-PGC-005 drug for moderate Corona Virus Disease(Covid-19).CTRI/2024/01/061531axai Life Sciences Pvt Ltd
已完成
2 期
A prospective clinicalstudy to evaluate the efficacy and safety of 101-PGC-005 for moderate COrona VIrus Disease(Covid-19).CTRI/2022/12/048284AXAI LIFE SCIENCES PVT. LTD.,
已完成
3 期
Randomised double-blind, comparative study to Evaluate the Efficacy, Safety of Cannabidiol oral solution versus matching Placebo for treatment of mild to moderate anxiety disordersCTRI/2023/01/049110eiutis Pharmaceuticals LLP178
已完成
3 期
A prospective, randomised, double-blind, multicentre, phase III clinical study on transarterial chemoembolisation (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) -Heidelberg Liver Cancer Study (HeiLivCa Study)CancerISRCTN24081794niversity of Heidelberg (Germany)204
